Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD133+ hematopoietic stem cells is an investigational cell therapy developed by St. Jude Children's Research Hospital for the treatment of high-risk pediatric solid tumors and lymphomas. The therapy involves the collection of a patient's own hematopoietic stem and progenitor cells, which are then processed using the CliniMACS device to positively select for the CD133 (Prominin-1) antigen. This selection process is designed to 'purge' the graft of contaminating tumor cells—which typically do not express CD133 in the targeted pediatric cancers—while retaining the essential cells required for hematopoietic recovery. The purified CD133+ cells are re-infused into the patient following a myeloablative conditioning regimen of high-dose busulfan and melphalan to restore bone marrow function and minimize the risk of post-transplant relapse caused by graft contamination.
- Other names
- CD133+ selected hematopoietic stem cellsautologous CD133+ selected stem cells
Beyond the preview
Go deeper on autologous CD133+ hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ hematopoietic stem cells.